Description Results

Symptomatic venous thromboembolism at the end of treatment 0.00 [0.00; NaN]

Certoparin, 8000 IU twice daily, 14 days (n=39)

vs.

Unfractioned heparin: bolus 5000 IU, infusion 20 IU/kg per hour (n=41)

sub group of patients with PE in a trial initially enrolling with acute deep vein thrombosis

open

Parallel groups

Sample size: 39/41

Primary endpoint: phlebographic Marder score

FU duration: 6 mo

Bleeding 2.00 [1.11; 3.61]

all cause death NaN [NaN; NaN]

Pulmonary embolism 0.00 [0.00; NaN]

Deep vein thrombosis 1.00 [0.52; 1.91]

asymptomatic proximal DVT 0.42 [0.23; 0.77]

all cause death NaN [NaN; NaN]

Bleeding 0.49 [0.05; 5.35]

Pulmonary embolism NaN [NaN; NaN]

Deep vein thrombosis 1.06 [0.71; 1.59]

all cause death 2.09 [0.40; 11.03]

Bleeding 1.09 [0.07; 17.06]

Pulmonary embolism ∞ [NaN; ∞]

Deep vein thrombosis 0.64 [0.36; 1.13]

major haemorrhage ∞ [NaN; ∞]

clinical PE NaN [NaN; NaN]

asymptomatic DVT ∞ [NaN; ∞]

wound hematoma 2.13 [0.61; 7.41]

symptomatic thromboembolism NaN [NaN; NaN]

transfusion 0.59 [0.35; 0.99]

death 0.39 [0.08; 1.95]

clinical PE 0.00 [0.00; NaN]

asymptomatic DVT 1.01 [0.50; 2.07]

wound hematoma 1.33 [0.23; 7.74]

death 0.63 [0.18; 2.16]

total haemorrhage 0.51 [0.20; 1.34]

major haemorrhage 2.83 [0.30; 26.70]

clinical PE 0.00 [0.00; NaN]

asymptomatic DVT 0.94 [0.06; 14.85]

wound hematoma 0.30 [0.06; 1.47]

symptomatic thromboembolism 0.00 [0.00; NaN]

transfusion 0.91 [0.71; 1.16]

asymptomatic DVT 0.30 [0.10; 0.88]

wound hematoma 1.50 [0.31; 7.19]

total haemorrhage 2.07 [0.53; 8.01]

major haemorrhage ∞ [NaN; ∞]

clinical PE ∞ [NaN; ∞]

asymptomatic DVT 0.83 [0.34; 2.00]

wound hematoma 2.00 [0.15; 26.19]

clinical PE 3.00 [0.26; 34.58]

asymptomatic DVT 1.50 [0.54; 4.14]

wound hematoma 0.74 [0.23; 2.33]

transfusion 1.31 [0.95; 1.81]

major haemorrhage 0.67 [0.11; 3.93]

clinical PE NaN [NaN; NaN]

asymptomatic DVT 0.33 [0.07; 1.63]

wound hematoma 0.70 [0.24; 2.10]

death 0.52 [0.05; 5.59]

major haemorrhage NaN [NaN; NaN]

clinical PE 1.00 [0.05; 18.57]

asymptomatic DVT 0.88 [0.31; 2.50]

wound hematoma ∞ [NaN; ∞]

major haemorrhage 0.97 [0.44; 2.15]

clinical PE ∞ [NaN; ∞]

proximal deep vein thrombosis 0.00 [0.00; NaN]

distal DVT 0.00 [0.00; NaN]

VTE (symptomatic or asymptomatic) 0.00 [0.00; NaN]

symptomatic VTE 0.00 [0.00; NaN]

Sandoz +0.5mg DHE (n=80)

vs.

Unfractionated heparin (n=80)

Sample size: 80/80

Primary endpoint:

FU duration:

certoparin 3000+0.5mg DHE, x1 (n=118)

vs.

Placebo (n=122)

double blind

Sample size: 118/122

Primary endpoint:

FU duration: 6 days

certoparin 3000+0.5mg DHE x1 (n=68)

vs.

placebo (n=71)

double blind

Sample size: 68/71

Primary endpoint:

FU duration: 6 days

Certoparin (dose 1 and dose 2) b.i.d. (n=84)

vs.

UFH 10 000 units (n=42)

Blind

Sample size: 84/42

Primary endpoint:

FU duration: 1 month

Certoparin 3000 + DHE (n=137)

vs.

UFH 10 000 units +DHE (n=132)

Blind

Sample size: 137/132

Primary endpoint:

FU duration: 7 days

Certoparin 3000 + DHE (n=103)

vs.

UFH 10 000 units (n=97)

Blind

Sample size: 103/97

Primary endpoint:

FU duration: 10 days

Certoparin 2500 + DHE (n=98)

vs.

UFH 10 000 units+DHE (n=103)

Open

Sample size: 98/103

Primary endpoint:

FU duration: 7 days

Certoparin 3000 + DHE (n=88)

vs.

UFH 10 000 units+DHE (n=91)

Blind

Sample size: 88/91

Primary endpoint:

FU duration:

Certoparin 3000 (n=205)

vs.

UFH 15 000 units (n=205)

Blind

Sample size: 205/205

Primary endpoint:

FU duration: 1 month

Certoparin 3000 (n=150)

vs.

UFH 15 000 units (n=150)

Blind

Sample size: 150/150

Primary endpoint:

FU duration: 10 days

Certoparin 3000 + DHE (n=99)

vs.

UFH 5 000 units+DHE (n=102)

Blind

Sample size: 99/102

Primary endpoint:

FU duration: 10 days

Certoparin 3000 + DHE (n=464)

vs.

UFH 10 000 units (n=452)

NA

Sample size: 464/452

Primary endpoint:

FU duration:

Certoparin 3000 anti Xa units (n=51)

vs.

UFH 15 000 units (n=53)

Blind

Sample size: 51/53

Primary endpoint:

FU duration:

Certoparin 3000 anti Xa units + DHE (n=47)

vs.

UFH 10 000 units + DHE (n=51)

Open

Sample size: 47/51

Primary endpoint:

FU duration:

Certoparin 3000 anti Xa units (n=336)

vs.

UFH 15 000 units (n=337)

Blind

Sample size: 336/337

Primary endpoint:

FU duration:

Certoparin 3000 anti Xa units (n=298)

vs.

UFH 10 000 units (n=296)

Blind

Sample size: 298/296

Primary endpoint:

FU duration:

Certoparin 3000 anti Xa units (n=179)

vs.

UFH 15 000 units (n=179)

Blind

Sample size: 179/179

Primary endpoint:

FU duration:

Certoparin 3000 anti Xa units (n=11542)

vs.

UFH 15 000 units (n=11536)

Blind

Sample size: 11542/11536

Primary endpoint:

FU duration:

Certoparin 3000 IU (n=176)

vs.

no prophylaxis (n=163)

open

Parallel groups

Sample size: 176/163

Primary endpoint:

FU duration: 15 days

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: